Your search for non small cell lung cancer returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

MPR First Report remove

Your search for non small cell lung cancer returned 17 results

Sort Results:

Relevant Recent
ASCO 2011

Quality of Life Significantly Improved with Erlotinib for NSCLC

Erlotinib improved progression-free survival when compared with gemcitabine + carboplatin as first-line treatment for EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer, according to the results of the OPTIMAL study presented at the American Society of Clinical Oncology's 2011 Annual Meeting.
ASCO 2011

Initial Phase 2 Results of Crizotinib Show Promise in Advanced ALK-Positive NSCLC

Data from an international, multicenter, open-label, Phase 2 clinical study suggested that crizotinib was safe and well-tolerated with preliminary evidence of improved symptoms and clinically meaningful antitumor activity in patients with pretreated ALK-rearranged metastatic non-small cell lung cancer, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.
ASCO 2011

Vadimezan Failed to Improve Efficacy When Combined with Carboplatin/Paclitaxel in NSCLC

ATTRACT-1, a global, double-blind randomized Phase 3 trial of carboplatin/paclitaxel (CP) coupled with the vascular-disrupting agent vadimezan (ASA404), although generally well-tolerated, did not demonstrate enhanced efficacy over placebo in patients with advanced non-small cell lung cancer (NSCLC), according to data presented at the American Society of Clinical Oncology's 2011 Annual Meeting.